Skip to main content
Fig. 5 | Translational Neurodegeneration

Fig. 5

From: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau

Fig. 5

Cognitive deficits of the dox-administered hTau368 mice. a Experimental procedure. Behavioral tests were conducted in sex-matched homozygous hTau368 mice following 2-month Veh/Dox administration. b Schematic illustration of the procedure of the novel-location recognition test. c Dox-treated hTau368 mice showed poorer performance in discriminating the object removed to a new place in the novel-location recognition test. Unpaired Student’s t-tests, *P < 0.05; n = 9–10 mice in each group d hTau368 mice with dox treatment showed lower rate of learning to find the platform in Morris-water maze test. Repeated measures ANOVA followed by Tukey’s post-hoc test. **P < 0.01; n = 9–10 mice in each group. e–g hTau368 mice with dox showed decreased time crossing (e) and distance travelling (f) in the target quadrant when the platform was removed in the Morris water maze. Representative heatmaps (g) showing the time and place of mice travelling in the water maze. Unpaired Student’s t-tests, *P < 0.05; n = 9–10 mice in each group. h–k hTau368 mice showed no cognitive deficits 3 months after retraction of dox both in the novel-location recognition test (i) and the Morris water maze test (j, k). Unpaired Student’s t-test or repeated measures ANOVA followed by Tukey’s post-hoc test. ns., nonsignificant, P > 0.05; n = 10–11 mice in each group

Back to article page